1995 related articles for article (PubMed ID: 8522359)
1. Anti-metastatic activity induced by the in vivo activation of purified protein derivative (PPD)-recognizing Th1 type CD4+ T cells.
Shinomiya Y; Harada M; Kurosawa S; Okamoto T; Terao H; Matsuzaki G; Shirakusa T; Nomoto K
Immunobiology; 1995 Aug; 193(5):439-55. PubMed ID: 8522359
[TBL] [Abstract][Full Text] [Related]
2. Th1 type CD4+ T cells may be a potent effector against poorly immunogenic syngeneic tumors.
Terao H; Harada M; Kurosawa S; Shinomiya Y; Okamoto T; Ito O; Sumichika H; Takenoyama M; Nomoto K
Biotherapy; 1994; 8(2):143-51. PubMed ID: 8924356
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with activated B cells pulsed with tumor-lysates can induce tumor-specific CD4+ T cells in vivo.
Ito O; Harada M; Takenoyama M; Tamada K; Li T; Abe K; Fujie H; Nomoto K
Immunobiology; 1998 Jul; 199(1):133-47. PubMed ID: 9717673
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Gorelik E
Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083
[TBL] [Abstract][Full Text] [Related]
5. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
6. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor mechanism of Z-100, an immunomodulatory Arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, on pulmonary metastases of B16F10 melanoma: restoration of helper T cell responses via suppression of glucocorticoid-genesis.
Oka H; Emori Y; Sasaki H; Shiraishi Y; Yoshinaga K; Kurimoto T
Microbiol Immunol; 2002; 46(5):343-51. PubMed ID: 12139394
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
9. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
11. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
12. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
[TBL] [Abstract][Full Text] [Related]
13. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
14. Anti-metastatic effect by in vivo administration of concanavalin A through augmentation of T-derived activated killer activity: efficacy to B16 melanoma expressed MHC antigen.
Taniguchi K; Kawano YI; Toshitani A; Karashima A; Nomoto K
Cell Immunol; 1989 May; 120(2):460-9. PubMed ID: 2785862
[TBL] [Abstract][Full Text] [Related]
15. Establishment of three PPD-reactive helper T cell clones with distinct functions in B cell activation.
Sano Y; Yamada G; Dobashi K; Mizuochi T; Hamaoka T; Takatsu K
J Immunol; 1984 Aug; 133(2):629-35. PubMed ID: 6234353
[TBL] [Abstract][Full Text] [Related]
16. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver.
Wiltrout RH; Herberman RB; Zhang SR; Chirigos MA; Ortaldo JR; Green KM; Talmadge JE
J Immunol; 1985 Jun; 134(6):4267-75. PubMed ID: 3989307
[TBL] [Abstract][Full Text] [Related]
17. NK 1+ CD4- CD8- alphabeta T cells in the peritoneal cavity: specific T cell receptor-mediated cytotoxicity and selective IFN-gamma production against B cell leukemia and myeloma cells.
Sugie T; Kubota H; Sato M; Nakamura E; Imamura M; Minato N
J Immunol; 1996 Nov; 157(9):3925-35. PubMed ID: 8892624
[TBL] [Abstract][Full Text] [Related]
18. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
19. Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours.
Algarra I; González A; Pérez M; Gaforio JJ; Garrido F
Clin Exp Immunol; 1996 Mar; 103(3):499-505. PubMed ID: 8608652
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy.
Cho D; Kim TG; Lee W; Hwang YI; Cho HI; Han H; Kwon O; Kim D; Park H; Houh D
J Invest Dermatol; 2000 May; 114(5):928-34. PubMed ID: 10771473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
